Haruhiko Ninomiya

1.9k total citations
82 papers, 1.3k citations indexed

About

Haruhiko Ninomiya is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Haruhiko Ninomiya has authored 82 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 38 papers in Immunology and 17 papers in Genetics. Recurrent topics in Haruhiko Ninomiya's work include Complement system in diseases (30 papers), Blood groups and transfusion (25 papers) and Platelet Disorders and Treatments (17 papers). Haruhiko Ninomiya is often cited by papers focused on Complement system in diseases (30 papers), Blood groups and transfusion (25 papers) and Platelet Disorders and Treatments (17 papers). Haruhiko Ninomiya collaborates with scholars based in Japan, United States and Switzerland. Haruhiko Ninomiya's co-authors include Toshiro Nagasawa, Tsukasa Abe, Yuichi Hasegawa, Harumi Y. Mukai, Yuzuru Kanakura, Tsutomu Shichishima, Hiroshi Kojima, Takuya Komeno, Hideki Nakakuma and Mitsuhiro Omine and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Haruhiko Ninomiya

80 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haruhiko Ninomiya Japan 21 634 550 321 273 164 82 1.3k
Louis Terriou France 20 807 1.3× 790 1.4× 567 1.8× 396 1.5× 138 0.8× 112 1.8k
Tsutomu Shichishima Japan 18 435 0.7× 665 1.2× 289 0.9× 335 1.2× 96 0.6× 94 1.0k
Sandra Fátima Menosi Gualandro Brazil 14 417 0.7× 279 0.5× 442 1.4× 162 0.6× 56 0.3× 40 846
Jamile M. Shammo United States 17 874 1.4× 296 0.5× 587 1.8× 147 0.5× 429 2.6× 79 1.5k
Dorottya Csuka Hungary 23 492 0.8× 727 1.3× 977 3.0× 227 0.8× 177 1.1× 95 1.6k
V. Aumann Germany 9 902 1.4× 1.3k 2.4× 400 1.2× 713 2.6× 110 0.7× 30 1.7k
Patrizia Noris Italy 36 2.2k 3.5× 314 0.6× 647 2.0× 230 0.8× 300 1.8× 91 2.9k
H. Heimpel Germany 15 706 1.1× 326 0.6× 295 0.9× 53 0.2× 113 0.7× 38 1.1k
Pascale Poullin France 14 388 0.6× 514 0.9× 219 0.7× 285 1.0× 123 0.8× 49 822
Pasquale Iacopino Italy 21 774 1.2× 294 0.5× 394 1.2× 40 0.1× 255 1.6× 72 1.3k

Countries citing papers authored by Haruhiko Ninomiya

Since Specialization
Citations

This map shows the geographic impact of Haruhiko Ninomiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haruhiko Ninomiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haruhiko Ninomiya more than expected).

Fields of papers citing papers by Haruhiko Ninomiya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haruhiko Ninomiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haruhiko Ninomiya. The network helps show where Haruhiko Ninomiya may publish in the future.

Co-authorship network of co-authors of Haruhiko Ninomiya

This figure shows the co-authorship network connecting the top 25 collaborators of Haruhiko Ninomiya. A scholar is included among the top collaborators of Haruhiko Ninomiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haruhiko Ninomiya. Haruhiko Ninomiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ikezoe, Takayuki, Akihiko Gotoh, Ioannis Tomazos, et al.. (2023). [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].. PubMed. 64(1). 9–17.
2.
Ishiyama, Ken, Yuji Yonemura, Tatsuya Kawaguchi, et al.. (2023). A longitudinal analysis of paroxysmal nocturnal haemoglobinuria‐type cells in patients with bone marrow failure: Results of a prospective multi‐centre study in Japan. British Journal of Haematology. 203(3). 468–476. 1 indexed citations
3.
Ikezoe, Takayuki, Hideyoshi Noji, Yasutaka Ueda, et al.. (2022). Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. International Journal of Hematology. 115(4). 470–480. 8 indexed citations
4.
Ninomiya, Haruhiko, Naoshi Obara, Yasuhisa Yokoyama, et al.. (2015). Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. SHILAP Revista de lepidopterología. 2015. 1–4. 1 indexed citations
5.
Kurita, Naoki, Naoshi Obara, Hidekazu Nishikii, et al.. (2013). Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. Blood Coagulation & Fibrinolysis. 24(6). 658–662. 3 indexed citations
6.
Kanakura, Yuzuru, Kazuma Ohyashiki, Tsutomu Shichishima, et al.. (2013). Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. International Journal of Hematology. 98(4). 406–416. 29 indexed citations
7.
Tomiyama, Yoshiaki, Yoshitaka Miyakawa, Shinichiro Okamoto, et al.. (2012). A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. Journal of Thrombosis and Haemostasis. 10(5). 799–806. 71 indexed citations
8.
Chiba, Shigeru, et al.. (2011). Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 152(5). 631–639. 36 indexed citations
9.
Kanakura, Yuzuru, Kazuma Ohyashiki, Tsutomu Shichishima, et al.. (2011). Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial. International Journal of Hematology. 93(1). 36–46. 52 indexed citations
10.
Kanakura, Yuzuru, Kazuma Ohyashiki, Tsutomu Shichishima, et al.. (2008). Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results.. Blood. 112(11). 3438–3438. 1 indexed citations
11.
Nishimura, Jun‐ichi, Yuzuru Kanakura, Russell E. Ware, et al.. (2004). Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan. Medicine. 83(3). 193–207. 186 indexed citations
12.
Nagasawa, Toshiro, et al.. (2000). Contribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood. 96(6). 2157–2162. 66 indexed citations
13.
Nagasawa, Toshiro, et al.. (2000). Contribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood. 96(6). 2157–2162. 21 indexed citations
14.
Ninomiya, Haruhiko, et al.. (2000). Inhibition of complement‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low‐molecular weight heparin. British Journal of Haematology. 109(4). 875–881. 27 indexed citations
15.
16.
Hasegawa, Yoshinori, Takayuki Itoh, Takuya Komeno, et al.. (1999). Non-Hodgkin's Lymphoma Followed by Plasmacytoma, Both Arising in a Thyroid Gland with Hashimoto's Disease. Leukemia & lymphoma. 35(5-6). 613–618. 2 indexed citations
17.
Ninomiya, Haruhiko, et al.. (1995). Clinical significance of elevated soluble interleukin‐6 receptor levels in the sera of patients with plasma cell dyscrasias. British Journal of Haematology. 91(1). 116–210. 30 indexed citations
18.
Ninomiya, Haruhiko, et al.. (1990). Three cases of acute syphilitic neuroretinitis. 41(11). 2088–2094. 3 indexed citations
19.
20.
Yamane, Kazuhide, et al.. (1983). Eosinophilic fasciitis with prominent immunologic abnormalities.. Japanese Journal of Medicine. 22(2). 134–136. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis Terriou Breakdown of academic impact, for papers by Tsutomu Shichishima Breakdown of academic impact, for papers by Sandra Fátima Menosi Gualandro Breakdown of academic impact, for papers by Jamile M. Shammo Breakdown of academic impact, for papers by Dorottya Csuka Breakdown of academic impact, for papers by V. Aumann Breakdown of academic impact, for papers by Patrizia Noris Breakdown of academic impact, for papers by H. Heimpel Breakdown of academic impact, for papers by Pascale Poullin Breakdown of academic impact, for papers by Pasquale Iacopino
Rankless by CCL
2026